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Primary erythermalgia is a rare disorder characterized by recurrent attacks of red, warm, and painful hands and/
or feet. The symptoms are generally refractory to treatment and persist throughout life. Five kindreds with multiple
cases of primary erythermalgia were identified, and the largest was subjected to a genomewide search. We detected
strong evidence for linkage of the primary erythermalgia locus to markers from chromosome 2q. The highest LOD
score (Z) was obtained with D2S2330 (Zmax p 6.51). Analysis of recombination events identified D2S2370 and
D2S1776 as flanking markers, on chromosome 2q31-32. This defines a critical interval of 7.94 cM that harbors
the primary erythermalgia gene. Affected members within the additional families also shared a common haplotype
on chromosome 2q31-32, supporting our linkage results. Identification of the primary erythermalgia gene will allow
a better clinical classification of this pleomorphic group of disorders.
Primary erythermalgia [MIM 133020] is a rare, hered-
itary syndrome of red, warm, and burning extremities
(Michiels and Van Joost 1988; Drenth and Michiels
1990). A recent literature analysis yielded 26 sporadic
cases, but the disorder has also been described in at least
seven families displaying an autosomal dominant mode
of inheritance (Krebs and Andres 1969; Thompson et
al. 1979; Cohen and Samorodin 1982; Kirby 1987; Mi-
chiels and Van Joost 1988; Michiels et al. 1989; Ge-
lehrter and Colins 1990; Finley et al. 1992; Drenth et
al. 1994; Martin et al. 1994). Primary erythermalgia
arises in childhood or adolescence with attacks of bi-
lateral symmetric pain. The symptoms are mainly con-
fined to the feet and lower legs but also can extend to
the hands, earlobes, and nose tip. Physical examination
reveals only local red-purple discoloration, with minor
congestion and increased local temperature. Symptoms
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can be precipitated by standing, slight exercise such as
walking, and exposure to heat, but relief can be obtained
by elevating the affected extremities and cooling them.
Typically, patients walk barefoot, even in wintertime,
and try to alleviate the intense burning by putting their
feet in buckets filled with ice. With age, the severity of
primary erythermalgia progresses, and symptoms extend
over a larger body area (e.g., over the ankles and lower
legs) and become constant. The treatment of primary
erythermalgia is cumbersome, and most patients have
tried a great variety of therapeutic options, with mixed
results (Davis et al. 2000). Several authors claim success
with continuous epidural infusion of various combina-
tions of bupivacaine and morphine in patients with pri-
mary erythermalgia, but a definitive treatment is not yet
available (D’Angelo et al. 1992).
The symptoms in primary erythermalgia are reminis-
cent of two other disorders: erythromelalgia and sec-
ondary erythermalgia. Erythromelalgia arises during
middle age and is linked to thrombocythemia, which
causes obliterative thrombosis of arterioles and digital
arteries (Michiels et al. 1985). Patients suffer from uni-
lateral burning distress of toes or fingers, which can be
immediately relieved by aspirin. Furthermore, eryther-
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malgia can be associated with underlying disorders or
the use of drugs and is then labeled as secondary ery-
thermalgia. These patients respond to treatment of the
underlying disorder or to stopping use of the drug re-
sponsible (Drenth et al. 1992; Hart 1996).
Thus far, laboratory investigations of patients with
primary erythermalgia failed to identify specific bio-
chemical abnormalities. Routine histopathological ex-
amination of affected skin lesions show only nonspecific
findings (Drenth et al. 1996), but one report suggests a
reduced density of skin autonomic nerve plexuses (Uno
and Parker 1983). A potential role of vasoactive neu-
ropeptides, such as substance P, was excluded, since we
did not recover it in fluid from artificial skin blisters
above erythermalgic skin (Drenth et al. 1997). It has
been shown that patients with erythermalgia have a
higher basal skin vasoconstrictor tone, with a diminished
vasoconstrictor response to cold challenge (Littleford et
al. 1999). However, this phenomenon was noted in both
primary and secondary erythermalgia, making it unlikely
that this represents a specific pathophysiological event.
Although these observations increase our understanding
of primary erythermalgia, they do not elucidate the un-
derlying pathophysiology or the responsible molecule.
In an effort to localize the gene for primary eryther-
malgia, we embarked on a genomewide search that re-
sulted in significant evidence for linkage of the gene re-
sponsible for primary erythermalgia on chromosome
2q31-32.
Appropriate informed consent was obtained from all
individuals who participated. A Medline search for the
period 1966–2000, using the keywords “familial,” “er-
ythermalgia,” and “erythromelalgia,” identified six fam-
ilies with primary erythermalgia, and another large kin-
dred has been published in a textbook of medical
genetics (Gelehrter and Colins 1990). One of the authors
(P. H. or J. D.) contacted either the first or the senior
author of each article, and contact was established with
five families (Thompson et al. 1979;Michiels et al. 1989;
Finley et al. 1992; Martin et al. 1994; Guillet et al.
1995). Studies of some members of these families have
been published elsewhere, and the pedigree structure of
those individuals participating in this study from families
1–5 is shown in figure 1A–1E. Family 1 came from Al-
abama, families 2 and 4 from France, family 3 from the
Netherlands, and family 5 from Canada. All patients
had a physical examination, and a medical history was
recorded. In total, 47 individuals were studied (28 were
affected, 9 of whom were male). Autosomal dominant
inheritance was confirmed by the presence of male-to-
male transmission (family 2). In the present study, the
diagnosis of primary erythermalgia was confirmed by
the patient’s history and the clinical findings. Specifically,
patients had to fulfill the set of criteria for primary er-
ythermalgia (Drenth andMichiels 1994), which included
(1) attacks of bilateral or symmetrical burning pain in
the hands or feet; (2) initiation or aggravation of attacks
by standing, exercise, or exposure to heat; (3) relief by
elevation and cold; (4) warmth, flushedness, and con-
gestion of the affected parts during attacks; and (5) the
disorder’s being refractory to treatment. Affected per-
sons typically manifested symptoms in the first decade
of life, and attacks persisted during life. There was no
consistent beneficial therapeutic regimen. Some patients
from family 2 benefited from pizotifen, an antiserito-
nergic drug, but its effect wore out after 1 year. Reex-
amination of family 1 revealed that individuals V:3 and
V:5 developed symptoms at the ages of 6 years and 2
years, respectively. Compared to her older sisters, indi-
vidual V:5 had more-severe symptoms. The first daugh-
ter in family 4 died as a result of septic shock, secondary
to infected wounds caused by excessive cooling. Indi-
viduals I:1 and I:2, from family 5, were first cousins.
Individual III:3, from family 5, underwent a bilateral
knee disarticulation, because of infected ulcers resulting
from excessive cooling. Individual III:2, from family 5,
underwent bilateral transfemoral amputations, because
of persistent infected ulcers. Individual IV:9, from family
1, who was severely affected, is thought to have died
from an overdose of drugs.
Genomic DNA was isolated and purified from pe-
ripheral blood by means of standard protocols (Miller
et al. 1988). For the purpose of the systematic genome
screening, we used fluorescently labeled short tandem
repeat polymorphisms (STRPs) from the Center for
Medical Genetics, Marshfield Medical Research Foun-
dation’s screening set 6A. The spacing of the marker set
varies from 10.0 cM to 24.2 cM. Additional markers
for fine mapping were obtained from the Ge´ne´thon
marker set (Dib et al. 1996). Marker order and inter-
marker distances were based on the existing Cooperative
Human Linkage Center linkage map. Genomic DNA (25
ng) was amplified in a 10-ml PCR reaction, containing
1# GeneAmp PCR Gold Buffer; 1.5 mM MgCl2; 25 ng
of fluorescent forward primer; 25 ng unlabeled reverse
primer; and 0.4 units of AmpliTaq Gold DNA poly-
merase. Initial denaturation was 15 s at 95C, followed
by 32 cycles of 30 s of denaturation at 95C, 30 s of
annealing at 55C, and 90 s of extension at 72C. Re-
actions were prepared using a Beckman Biomek 2000
robot system and were performed in 384-well plates.
Amplification was done using a dual 384-well–equipped
GeneAmp PCR System 9700 (Applied Biosystems). PCR
products were pooled and loaded on an ABI 377 au-
tomated sequencer (filterset D; 5% denaturing FMC
LongRanger acrylamide gel). Data were analyzed by
means of ABI GeneScan 3.1 and ABI Genotyper 2.1
software. Binning of the alleles and preparation of pre-
linkage files were performed using Linkage Designer 1.0
(Van Camp et al. 1997).
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Figure 1 Pedigree of five families (A, family 1; B, family 2; C, family 3; D, family 4; E, family 5, with autosomal dominant–inherited
primary erythermalgia. Females are indicated by circles and males by squares. Blackened figures denote affected individuals, and figures with
slashes denote deceased individuals. Genotypes for chromosome 2 markers were determined for all living persons shown. Haplotypes for boxed
portions of the pedigree are presented.
Linkage analysis and calculation of the two-point
LOD scores between the disease locus and each individ-
ual marker was performed using the MLINK and ILINK
programs of the LINKAGE package (version 5.1) (Lab-
oratory of Statistical Genetics, Rockefeller University)
(Lathrop and Lalouel 1984). Maximum LOD and lo-
cation scores were calculated for each marker under the
assumption that erythermalgia was an autosomal dom-
inant disorder. Because of the early onset of the disease
and the severity of the symptoms, we assumed full pen-
etrance. In view of the relative rarity of the disease, the
frequency of the abnormal allele was set at .0001. Re-
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Table 1
Two-Point Linkage Analysis Data at Various Recombination
Fractions, for the Primary Erythermalgia–Susceptibility Gene and
for Markers on Chromosome 2q, in Family 1
Marker 0 .01 .05 .1 .2 .3 .4
D2S1353   4.33 4.6 4.35 3.49 2.41 1.2
D2S2370   2.24 2.64 2.55 2.04 1.37 .63
D2S2157 3.83 3.75 3.44 3.05 2.24 1.41 .57
D2S111 6.31 6.2 5.77 5.22 4.03 2.76 1.39
D2S2330 6.51 6.4 5.96 5.37 4.14 2.82 1.41
D2S2345 6.19 6.09 5.66 5.11 3.95 2.7 1.36
D2S1776   .83 1.32 1.36 1.12 .73 .3
D2S1391   3.89 .74 .32 .91 .85 .51
combination frequency (v) was assumed to be equal for
males and females. No phenocopies were allowed, and
allele frequencies were calculated from all genotyped
families. Multipoint analysis was performed using the
LINKMAP program by subsequent three-point linkage
analysis on all tested markers. Haplotypes were con-
structed in such a way as to minimize the number of
crossovers in each family.
We started to genotype all available individuals from
the largest family (family 1), and, using an semiauto-
mated systematic genome scan for this family, we ob-
tained positive LOD scores at v p .01 for two markers
(D2S1353 and D2S1776) on chromosome 2q. Further
refinement of this region by saturation with additional
markers within it (table 1) confirmed these findings, and
two-point linkage analysis yielded a maximum LOD
score (Zmax) of 6.51 at v p 0 for marker D2S2330.
Subsequent multipoint analysis yielded a Zmaxp 7.05 at
v p 0 for marker D2S2330 (fig. 2). There was no sig-
nificant linkage with markers from other chromosomal
regions. Haplotypes were then constructed by parsimony
(fig. 1). Several recombinants that defined the limits of
the erythermalgia-susceptibility region were detected.
The recombination events in family 1 suggest that the
region is limited by marker D2S2370 on the centromeric
side (V:5) and by marker D2S1776 on the telomeric side
(IV:3). Therefore, the critical region spans 7.94 cM on
the sex-averaged linkage map. We then tested the rele-
vant chromosome 2 markers in four other families with
primary erythermalgia who, by themselves, were not
powerful enough to give significant evidence for linkage,
and we constructed haplotypes for all tested markers for
these families. This revealed that affected individuals
within these primary erythermalgia families share a com-
mon allele for markers in the susceptibility region that
is not shared by healthy individuals. This suggests that
the gene responsible for the disorder in these families is
also localized to chromosome 2q. A recombination event
for marker D2S2157 in family 5 (individual III:5) would
reduce the critical region to 3.59 cM on the sex-averaged
linkage map. However, in this report, the haplotypes in
this family cannot be determined unambiguously, be-
cause several markers in this region are not fully infor-
mative. Therefore, a conservative estimate suggests that
the maximum region of linkage is defined by a 7.94-cM
critical interval, extending from D2S2370 to D2S1776,
that must contain the erythermalgia gene.
Given the rarity of primary erythermalgia, it might be
hypothesized that there is a founder effect. The families
originated from various parts of Northern Europe, the
United States, and Canada, and a common ancestor
could not be determined. The haplotype of the five af-
fected families did not show any common region in the
disease-bearing chromosomes. This, in combination
with the relative small distance of the linked interval,
suggests that the mutation is different in each family.
Given the phenotypical similarities between the familial
and isolated cases of primary erythermalgia, the question
arises as to whether they share a molecular defect in the
same gene. This would, however, imply some degree of
nonpenetrance, since none of the parents of the isolated
patients have the disease. The primary erythermalgia in
our kindred was fully penetrant—that is, all patients
carried the disease-associated haplotype. The identifi-
cation of the causative gene in primary erythermalgia
will be necessary to address this question.
Despite the uniform presentation of primary eryther-
malgia, the intensity of symptoms did vary even within
families. Although, in one family, two siblings needed
constant cooling with subsequent severe excoriation of
the skin eventually leading to limb amputation, the
mother and another brother had much milder symptoms
(Kirby 1987). Although primary erythermalgia is not a
life-threatening disease, we saw severe and potential le-
thal complications of the symptoms. Excessive cooling
of the skin led in at least three cases to progressive ul-
cerative inflammation of the extremities, which highly
increases the likelihood of a gram-positive septic shock.
Indeed, this was the cause of death in one of our patients.
It is suggested that symptoms in erythermalgia, re-
gardless of cause, develop as a result of maldistribution
of available perfusion in favor of arteriovenous anas-
tomoses, resulting in skin warming, followed by in-
creased metabolism and subsequent hypoxia (Mork et
al. 2000). Indeed, in patients with erythermalgia, there
is increased skin blood flow in areas of AV shunts during
attacks. A study with skin perfusion indicated that they
have a paradoxal increased vascular tone, leading to a
vasoconstrictor tendency, perhaps resulting from hy-
poxic injury to the microvasculature (Littleford et al.
1999). This correlates with the pathological changes ob-
served in primary erythermalgia, in which a perivascular
mononuclear infiltrate, thickened blood-vessel basement
membranes, abundant perivascular edema, and endo-
thelial cell swelling can be observed (Drenth et al. 1996).
The protein coded by the autosomal dominant gene
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Figure 2 Multilocus analysis, with the primary erythermalgia gene, against a fixed genetic map of linked markers for family 1. Order of
markers and distances are taken from published sources (Dib et al. 1996). The highest probability for location of the primary erythermalgia
gene is in the region between D2S1353 and D2S1391.
for primary erythermalgia is unknown, but it might be
presumed, given the disturbed microcirculatory flow, to
be expressed in endothelial cells and to affect endothelial
function. A search of the GeneMap ’99 database for the
chromosome 2q linkage interval reveals several genes
and numerous expressed sequence tags (ESTs) with no
known function in most instances. On the basis of avail-
able functional information for these ESTs, no obvious
candidate gene for primary erythermalgia emerges, but
the linkage interval does encompass two possible can-
didate genes: alpha-6 integrin and interleukin (IL) 17.
Patients with an absence of alpha-6 integrin have junc-
tional epidermolysis bullosa with pyloric atresia and
esophageal stenosis (MIM 226730). Primary eryther-
malgia differs phenotypically, and it is difficult to gen-
eralize the clinical description to other mutations in the
alpha-6 integrin gene. IL17 (MIM 603149) induces the
production of IL6, increases the surface expression of
intracellular adhesion molecules in cultured fibroblasts,
and is probably involved in osteoclastogenesis. It is dif-
ficult to foresee whether IL17 will have a role in the
pathogenesis of erythermalgia.
Further refinement of critical region is not easy to
achieve, given the relatively small genetic distance of the
linked interval and the limited number of families with
the syndrome that has been described. A positional (can-
didate)-gene approach that includes extensive analysis
of the newly available genomic-sequence datamight now
allow the identification of the incriminated gene. Pursuit
of the causative gene for primary erythermalgia may lead
to diagnostic and therapeutic approaches for individuals
with this rare disease. Understanding the molecular pa-
thology will not only shed light on pathogenic mecha-
nisms in primary erythermalgia but may also benefit pa-
tients with more-common entities related to an impaired
skin microcirculation, such as Raynaud’s syndrome.
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